Performance Evaluation of an Ultra-Sensitive Assay for NSCLC Biomarker Testing

Home > Science Hub > Performance Evaluation of an Ultra-Sensitive Assay for NSCLC Biomarker Testing
Back to the list

June 23, 2025

Nathalie Bernard¹, Magdalena Stolarek-Januszkiewicz², Christina Xyrafaki², Ana-Luisa Silva², Justyna Mordaka², Sara Diels¹, Dirk Goossens¹, Lien Heyrman¹, Bart Tegenbos¹, Jurgen Del Favero

You might also be interested by

Press Releases

CellCarta and Pillar Biosciences Announce Multi-Year Global Strategic Partnership to Expand Rapid, Decentralized Tumor Profiling for Oncology Clinical Trials

April 7, 2026

More info

News

CellCarta and Lunit Announce Strategic Collaboration to Accelerate AI-Enabled Digital Pathology for Companion Diagnostic Programs

March 30, 2026

More info

News

CellCarta Secures Global Exclusivity for Biofidelity's Aspyre® Lung to Advance Targeted Lung Cancer Testing

March 18, 2026

More info

Posters

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

March 3, 2026

More info